This report provides an in-depth analysis of the Roche-NVIDIA AI factory and its implications for GLP-1 drug manufacturing
Jalandra R, Dalal N, Yadav AK, Verma D, Sharma M, Singh R, Khosla A, Kumar A, Solanki PR
Utilization of PBPK Modeling Approaches to Assess DDIs Caused by Mechanisms of Actions Evaluating the mechanism of action (eg, delayed gastric emptying, reduced fat mass and inflammation, and changes in GFR)-mediated DDIs of GLP-1 RAs and a dual GLP-1/GIP RA is often challenging to control for and clinical studies are costly
The advent of incretin-based therapies and the expansion to multi-receptor agonist peptides targeting glucagon-like peptide 1 (GLP1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin receptors has transformed obesity treatment, demonstrating average weight loss of more than 20% in humans and improvements in a broad range of obesity-related comorbidities
Many clinicians want to see ferritin comfortably above the very bottom of the range when someone is shedding, because low iron stores are a recognized contributor
bmj 2021, 373
